Yıl: 2020 Cilt: 68 Sayı: 1 Sayfa Aralığı: 66 - 75 Metin Dili: Türkçe DOI: 10.5578/tt.69278 İndeks Tarihi: 30-11-2020

Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım

Öz:
Akciğer kanseri dünya genelinde kanserle ilişkili ölümlerin başlıca nedeniolmaya devam etmektedir. Son 20 yılda kanser biyolojisi ve patogenezi hakkındaki bilgiler artmış, immün kontrol noktası inhibitörleri (İKNİ) kullanımasunulmuş ve böylece solid kanserlerin tedavisinde önemli bir dönem başlamıştır. Bu derlemede; tedavide yenilikler, immünoterapi ve tedavide multidisipliner yaklaşım çerçevesinde akciğer kanseri ele alınmıştır. Küçük hücreli dışıakciğer kanseri (KHDAK) en sık görülen ve özellikleri nedeniyle İKNİ tedavisinden ideal olarak yararlanabilecek akciğer kanseri türü olması nedeniyleyazının odak noktasını oluşturmuştur. Bu derleme, akciğer kanseri tedavisindeimmünoterapi yaklaşımının göğüs hastalıkları başta olmak üzere tüm branşlarda multidisipliner farkındalığını artırmayı ve yönetimi hakkında bilgi sağlamayıamaçlayan ilk Türkçe derlemedir. Ayrıca bu derleme, KHDAK tedavisinde İKNİkullanımına ilişkin son klinik çalışmaların dikkat çekici sonuçlarını sunmasıaçısından önem teşkil etmektedir. İmmünoterapi kanser tedavisinde yeni bir dönem başlatmıştır ve İKNİ tedavisinin kendine özgü etki mekanizması yeni bazı advers olay grubunun ortaya çıkmasına nedenolmuştur, bunlar arasında pnömonitis özellikle önemlidir ve advers olaylar konusunda gerektiğinde hastaların ilgili uzmanlık dalları ilekonsülte edilmesi gerekmektedir. Akciğer kanserinde tedavi, hastanın özellikleri, histolojik özellikler, genetik durum göz önünde bulundurularak her bir hastaya özel planlanmalı ve akciğer kanserli bir hastanın tanısal değerlendirilmesi ve en uygun şekilde tedavisi içingöğüs hastalıkları, göğüs cerrahisi, tıbbi onkoloji, radyasyon onkolojisi, patoloji ve radyoloji uzmanlık dalları arasında işbirliği sağlanmalıdır. Bununla birlikte, aile hekimleri de akciğer kanserinin erken tanınmasında ve ayrıca hastalarını tütün bırakmayı teşvik ederekkanserin önlenmesinde önemli rol oynayabilirler. Ayrıca, toplumda farkındalık yaratmak ve erken tanı için akciğer kanseri yönündentarama çalışmaları yapmak hedeflenmelidir
Anahtar Kelime:

Immunotherapy and multidisciplinary approach to treatment in lung cancer

Öz:
Lung cancer remains as the main cause of cancer-related deaths worldwide. Over the last two decades, information about biology and pathogenesis of cancer has increased, immune checkpoint inhibitors (ICIs) have been introduced, and thus a significant period has started in treatment of solid cancers. This review discussed lung cancer in the framework of innovations in treatment, immunotherapy, and multidisciplinary approach to treatment. Non-small cell lung cancer (NSCLC) was the focal point of this article as it is the most frequent lung cancer type and the type of lung cancer which can ideally benefit from ICI treatment due to its characteristics. This review is the first review in Turkish language, which aimed to raise the multidisciplinary awareness about immunotherapy approach in lung cancer treatment in all branches, primarily in chest diseases, and to provide information about its management. Moreover, this review has importance as it presents the remarkable results of recent clinical trials on the use of ICIs in NSCLC treatment. Immunotherapy has initiated a new era in cancer treatment; the specific mechanism of action of ICIs has resulted in a group of some new adverse events, among which pneumonitis is particularly important and when necessary, patients are needed to be consulted with relevant specialties about adverse events. Lung cancer treatment should be planned specific to each patient by considering patient characteristics, histological features, and genetic status and specialty areas of chest diseases, thoracic surgery, medical oncology, radiation oncology, pathology, and radiology should collaborate together for diagnostic evaluation and optimal treatment of a lung cancer patient. Moreover, family physicians may have an important role in early diagnosis of lung cancer and in preventing lung cancer by encouraging their patients regarding tobacco cessation. Moreover, screening studies for lung cancer should be targeted to create awareness in society and for early diagnosis.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Naran K, Nundalall T, Chetty S, Barth S. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. Front Microbiol 2018;9:3158.
  • 2. Global Cancer Observatory (GCO). Cancer Today. Cancer Fact Sheet. Erişim tarihi: 13 Mart 2019. Available from: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lungfact-sheet.pdf.
  • 3. McIntyre A, Ganti AK. Lung cancer-A global perspective. J Surg Oncol 2017;115:550-4.
  • 4. Global Cancer Observatory (GCO). Cancer Today. Turkey Fact Sheet. Erişim tarihi: 13 Mart 2019. Available from: http://gco.iarc.fr/today/data/factsheets/populations/792-turkey-fact-sheets.pdf.
  • 5. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health 2019;85:pii: 8.
  • 6. Latimer KM, Mott TF. Lung cancer: Diagnosis, treatment principles, and screening. Am Fam Physician 2015;91:250- 6.
  • 7. Lim SW, Ahn MJ. Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer. Korean J Intern Med 2019;34:50-9.
  • 8. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of lung tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 2015;10:1243-60.
  • 9. Kanwal B, Biswas S, Seminara RS, Jeet C. Immunotherapy in advanced non-small cell lung cancer patients: ushering chemotherapy through the checkpoint inhibitors? Cureus 2018;10:e3254.
  • 10. Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C. Progress and prospects of early detection in lung cancer. Open Biol 2017;7:170070.
  • 11. Sánchez de Cos Escuín J. New immunotherapy and lung cancer. Arch Bronconeumol 2017;53:682-7.
  • 12. Wojas-Krawczyk K, Kalinka E, Grenda A, Krawczyk P, Milanowski J. Beyond PD-L1 markers for lung cancer immunotherapy. Int J Mol Sci 2019;20(8). pii: E1915.
  • 13. Barnet MB, Cooper WA, Boyer MJ, Kao S. Immunotherapy in non-small cell lung cancer: Shifting prognostic paradigms. J Clin Med 2018;7:E151.
  • 14. Abdel-Rahman O, Morris D. Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. Immunotherapy 2019;11:149-53.
  • 15. Cavanna L, Citterio C, Orlandi E. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget 2019;10:209-15.
  • 16. Dong J, Li B, Zhou Q, Huang D. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. J Evid Based Med 2018;11:278-87.
  • 17. Prelaj A, Tay R, Ferrara R, Chaput N, Besse B, Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer 2019;106:144-59.
  • 18. Remon J, Hendriks LE, Cabrera C, Reguart N, Besse B. Immunotherapy for oncogenic-driven advanced nonsmall cell lung cancers: Is the time ripe for a change? Cancer Treat Rev 2018;71:47-58.
  • 19. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 2017;12:208-22.
  • 20. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540-50.
  • 21. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65.
  • 22. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
  • 23. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, et al. Nivolumab versus Docetaxel in previously treated patients with advanced non-small-cell lung cancer: TwoYear outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017;35:3924-33.
  • 24. Felip Font E, Gettinger SN, Burgio MA, Antonia SJ, Holgado E, Spigel DR, et al. Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017;28(Suppl 5).
  • 25. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39.
  • 26. Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of Nivolumab in previously treated advanced non-small-cell lung cancer: Results from the CA209-003 study. J Clin Oncol 2018;36:1675-84.
  • 27. Brahmer J, Borghaei H, Ramalingam SS, Horn L, Holgado E, Pluzanski A, et al. Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response [abstract]. Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; 2019 Mar 29-Apr 3; Atlanta, GA, USA. Philadelphia (PA): AACR; 2019. Abstract 19-LB-7988- AACR.
  • 28. Gettinger S, Borghaei H, Brahmer J, Chow LQM, Burgio MA, de Castro Carpeno J, et al. Pooled analysis of checkmate 017 and 057: 5-year outcomes with nivolumab vs docetaxel in previously treated NSCLC. Presented at: IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer; September 7-10, 2019; Barcelona, Spain. Abstract OA14.04.
  • 29. Shafique M, Tanvetyanon T. Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. Expert Opin Biol Ther 2019;19:225-32.
  • 30. Martinez P, Peters S, Stammers T, Soria JC. Immunotherapy for the first-line treatment of patients with metastatic nonsmall cell lung cancer. Clin Cancer Res 2019;25:2691-8.
  • 31. Ghysen K, Vansteenkiste J. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer. Curr Opin Oncol 2019;31:13-7.
  • 32. Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: Insights from long-term survivors. Cancer Immunol Immunother 2019;68:341-52.
  • 33. Calles A, Aguado G, Sandoval C, Álvarez R. The role of immunotherapy in small cell lung cancer. Clin Transl Oncol 2019;21:961-76
  • 34. Lehman JM, Gwin ME, Massion PP. Immunotherapy and targeted therapy for small cell lung cancer: There is hope. Curr Oncol Rep 2017;19:49.
  • 35. U.S. Food and Drug Administration. Erişim tarihi: 16.07.2019. Available from: https://www.fda.gov/drugs/ resources-information-approved-drugs/ fda-grants-nivolumab-accelerated-approv - al-third-line-treatment-metastatic-small-cell-lung-cancer.
  • 36. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95.
  • 37. U.S. Food and Drug Administration. Erişim tarihi: 16.07.2019. Available from: https://www.fda.gov/drugs/ drug-approvals-and-databases/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer
  • 38. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 2018;379:2220-9.
  • 39. U.S. Food and Drug Administration. Erişim tarihi: 16.07.2019. Available from: https://www.fda.gov/drugs/ resources-information-approved-drugs/fda-approves-pembrolizumab-metastatic-small-cell-lung-cancer
  • 40. Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the Phase Ib KEYNOTE-028 Study. J Clin Oncol 2017;35:3823-9.
  • 41. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.
  • 42. Nishino M, Hatabu H, Hodi FS, Ramaiya NH. Drugrelated pneumonitis in the era of precision cancer therapy. Precis Oncol 2017. Epub 2017 May 26.
  • 43. Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y. The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: A meta-analysis. Front Pharmacol 2018;9:1430.
  • 44. Xu Z, Yi F, Yu D, Xu J, Wei Y, Zhang W. Nivolumab provides improved effectiveness and safety compared with docetaxel as a second-line treatment for advanced nonsmall cell lung cancer: A systematic review and meta-analysis. Cancer Med 2019;8:629-42.
  • 45. Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events. J Immunother Cancer 2018;6:101.
  • 46. Gaga M, Powell CA, Schraufnagel DE, Schönfeld N, Rabe K, Hill NS, et al. An official American Thoracic Society/ European Respiratory Society statement: The role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med 2013;188:503-7.
  • 47. De Marinis F, Barberis M, Barbieri V, Marchianò A, Gasparini S, Migliorino MR, et al. Diagnosis and first-line treatment of non-small cell lung cancer in the era of novel immunotherapy: Recommendations for clinical practice. Expert Rev Respir Med 2019;13:217-28.
  • 48. Cancer Research Institute. Erişim tarihi: 27.06.2019. Available from: https://www.cancerresearch.org/join-thecause/cancer-immunotherapy-month/wear-white-day).
APA Karadurmuş N, KAYA A, Göksel T, YILMAZ Ü, Tulek N (2020). Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. , 66 - 75. 10.5578/tt.69278
Chicago Karadurmuş Nuri,KAYA AKIN,Göksel Tuncay,YILMAZ ÜLKÜ,Tulek Necla Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. (2020): 66 - 75. 10.5578/tt.69278
MLA Karadurmuş Nuri,KAYA AKIN,Göksel Tuncay,YILMAZ ÜLKÜ,Tulek Necla Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. , 2020, ss.66 - 75. 10.5578/tt.69278
AMA Karadurmuş N,KAYA A,Göksel T,YILMAZ Ü,Tulek N Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. . 2020; 66 - 75. 10.5578/tt.69278
Vancouver Karadurmuş N,KAYA A,Göksel T,YILMAZ Ü,Tulek N Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. . 2020; 66 - 75. 10.5578/tt.69278
IEEE Karadurmuş N,KAYA A,Göksel T,YILMAZ Ü,Tulek N "Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım." , ss.66 - 75, 2020. 10.5578/tt.69278
ISNAD Karadurmuş, Nuri vd. "Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım". (2020), 66-75. https://doi.org/10.5578/tt.69278
APA Karadurmuş N, KAYA A, Göksel T, YILMAZ Ü, Tulek N (2020). Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. Tüberküloz ve Toraks, 68(1), 66 - 75. 10.5578/tt.69278
Chicago Karadurmuş Nuri,KAYA AKIN,Göksel Tuncay,YILMAZ ÜLKÜ,Tulek Necla Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. Tüberküloz ve Toraks 68, no.1 (2020): 66 - 75. 10.5578/tt.69278
MLA Karadurmuş Nuri,KAYA AKIN,Göksel Tuncay,YILMAZ ÜLKÜ,Tulek Necla Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. Tüberküloz ve Toraks, vol.68, no.1, 2020, ss.66 - 75. 10.5578/tt.69278
AMA Karadurmuş N,KAYA A,Göksel T,YILMAZ Ü,Tulek N Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. Tüberküloz ve Toraks. 2020; 68(1): 66 - 75. 10.5578/tt.69278
Vancouver Karadurmuş N,KAYA A,Göksel T,YILMAZ Ü,Tulek N Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım. Tüberküloz ve Toraks. 2020; 68(1): 66 - 75. 10.5578/tt.69278
IEEE Karadurmuş N,KAYA A,Göksel T,YILMAZ Ü,Tulek N "Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım." Tüberküloz ve Toraks, 68, ss.66 - 75, 2020. 10.5578/tt.69278
ISNAD Karadurmuş, Nuri vd. "Akciğer kanserinde immünoterapi ve tedavide multidisipliner yaklaşım". Tüberküloz ve Toraks 68/1 (2020), 66-75. https://doi.org/10.5578/tt.69278